生产企业：MAIA Biotechnology, Inc.
Ateganosine (6-thio-2'-deoxyguanosine, THIO, 6-thio-dG) is a first-in-class investigational telomere-targeting anticancer agent developed by MAIA Biotechnology that selectively damages cancer-cell telomeres while activating the body's antitumor immune response. It is in clinical development for non-small cell lung cancer as a second- or later-line treatment for telomerase-positive tumors progressing after checkpoint inhibitors.
Ateganosine (6-thio-2'-deoxyguanosine, THIO, 6-thio-dG) is a first-in-class investigational telomere-targeting anticancer agent developed by MAIA Biotechnology that selectively damages cancer-cell telomeres while activating the body's antitumor immune response. It is in clinical development for non-small cell lung cancer as a second- or later-line treatment for telomerase-positive tumors progressing after checkpoint inhibitors.
Ateganosine (6-thio-2'-deoxyguanosine) is a first-in-class telomere-targeting agent: it uses the modified nucleotide 6-thio-2'-deoxyguanosine, which is selectively recognized and incorporated by telomerase into cancer-cell telomeres, inducing telomerase-dependent telomeric DNA modification, DNA damage responses and selective cancer-cell death, while activating the body's antitumor immune response.
共 1 项相关疾病
